A 56-day randomized controlled trial of 60 patients evaluated a topical formulation combining Centella asiatica extracellular vesicles with Fc-fusion modified rIGF-1 and rFGF-7. The complete formulation showed improvements over placebo in hair shaft thickness (28 μm vs 14 μm increase), hair density (24% vs 12% increase), and hair loss reduction (64% vs 43%). The predominantly female cohort (mean age 36) limits generalizability to older patients with androgenetic alopecia. Notable limitations include the short study duration relative to follicular cycling, industry funding from the product manufacturer, and preprint status without peer review.

Source: medRxiv